CN106858605A - A kind of probiotics calcium functional food for preventing and treating bone information relevant disease - Google Patents
A kind of probiotics calcium functional food for preventing and treating bone information relevant disease Download PDFInfo
- Publication number
- CN106858605A CN106858605A CN201611214057.7A CN201611214057A CN106858605A CN 106858605 A CN106858605 A CN 106858605A CN 201611214057 A CN201611214057 A CN 201611214057A CN 106858605 A CN106858605 A CN 106858605A
- Authority
- CN
- China
- Prior art keywords
- hundred million
- viable bacterias
- probiotics
- freeze
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 43
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 43
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 239000011575 calcium Substances 0.000 title claims abstract description 23
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 23
- 235000013376 functional food Nutrition 0.000 title claims abstract description 15
- 201000010099 disease Diseases 0.000 title claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 14
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims abstract description 33
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 20
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 13
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 10
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims abstract description 5
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 5
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 5
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 5
- 229940004120 bifidobacterium infantis Drugs 0.000 claims abstract description 5
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 5
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 4
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 4
- 230000006020 chronic inflammation Effects 0.000 claims abstract description 4
- 229940011871 estrogen Drugs 0.000 claims abstract description 4
- 239000000262 estrogen Substances 0.000 claims abstract description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 4
- 229920001202 Inulin Polymers 0.000 claims abstract description 3
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 3
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 3
- 208000029725 Metabolic bone disease Diseases 0.000 claims abstract description 3
- 206010027476 Metastases Diseases 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 3
- 206010049088 Osteopenia Diseases 0.000 claims abstract description 3
- 201000011510 cancer Diseases 0.000 claims abstract description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 3
- 229940029339 inulin Drugs 0.000 claims abstract description 3
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 3
- 230000009401 metastasis Effects 0.000 claims abstract description 3
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 108010048734 sclerotin Proteins 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 208000001277 chronic periodontitis Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 241000186660 Lactobacillus Species 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 5
- 208000019664 bone resorption disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000004072 osteoblast differentiation Effects 0.000 description 7
- 230000001599 osteoclastic effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000011132 calcium sulphate Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 235000019624 protein content Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000010266 Aggressive Periodontitis Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical class [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000004407 iron oxides and hydroxides Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 201000006727 periodontosis Diseases 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of probiotics calcium functional food for preventing and treating bone information relevant disease.The described bone resorption disease related to osteoporosis be：Lack the osteoporosis for causing, osteoporosis caused by chronic inflammation, the osteopenia shape caused after cancer bone metastasis etc. including women postmenopausal estrogen.Every gram described of probiotics calcium functional food food includes following components：Calcium carbonate 0.1g, the bifidobacterium infantis freeze-dried powder of 3.0 3.1 hundred million viable bacterias, the bifidobacterium adolescentis freeze-dried powder of 3.0 3.1 hundred million viable bacterias, the bifidobacterium lactis freeze-dried powder of 3.0 3.1 hundred million viable bacterias, the Lactobacillus casei freeze-dried powder of 3.0 3.1 hundred million viable bacterias, the Lactobacillus rhamnosus freeze-dried powder of 3.0 3.1 hundred million viable bacterias, the lactobacillus acidophilus freeze-dried powder of 3.0 3.1 hundred million viable bacterias, inulin 0.1g, remaining be maltodextrin.
Description
Technical field
It is related for preventing and treating bone information in particular to one kind the invention belongs to biomedicine technical field
The probiotics calcium functional food of disease.
Background technology
The lasting self-renewing of bone tissue is for calcium content in blood of human body and maintains the tough with important of sclerotin
Physiological significance.The dynamic equilibrium of bone information (being performed by osteoclast) and bon e formation (being performed by Gegenbaur's cell) is characterized in,
This balance will trigger various diseases, such as osteoporosis once being broken, periodontosis and handkerchief Zhe Shi diseases etc..Osteoporosis is faced
Bed shows as sclerotin reduction, and bone information enhancing and fracture probability are raised.Osteoporosis is a kind of common disease, especially in menopause
The incidence of disease is very high in women afterwards.The women of about 40%50 years old and the above had the experience of fracture according to statistics.
The process of the formation of bone be by a series of hormone (such as androgen, estrogen, parathryoid hormone), growth because
Sub (such as transforming growth factor beta, bone morphogenetic protein, type-1 insulin like growth factor and Vitamin C, D etc.) and mineral matter
Osteoblast Differentiation is carried out in the presence of calcium, magnesium etc. are common, the osteocyte for eventually becoming maturation participates in the formation of new bone.
Probiotics is the intestinal microflora with body symbiosis, and they are passing through very long evolutionary process together with the mankind
In, probiotics is closed with body Absorption And Metabolism to divide.Modern study shows that probiotics synthesizes the nutrition of a large amount of needed by human body
Composition, including there is the trace element of the vitamin D, vitamin K and other assistance absorption calcium of substantial connection to calcium uptake.Cause
This, is used by calcium carbonate with the compatibility of various a certain proportion of probiotics, can with multi-angle increase calcium absorptivity, play compared with
Good calcium supplementing effect.
On the other hand, in the diet of human body, substantial amounts of calcium is also contained.Body calcium deficiency, also reflects body to food
There are some problems in the absorption of middle calcium.By probiotic supplemented, organismic internal environment can be improved, and obtain the promotion food of abundance
The various nutriments of middle calcium uptake, and then improve the ability that body absorbs calcium in food.Therefore, by the certain proportioning of supplement
Probiotics, the calcium during body can be made to absorb more foods.And then treatment of the improvement to osteoporosis.
The content of the invention
The present invention provides a kind of probiotics calcium functional food, it is possible to increase bone density and blood calcium, can be used to preventing and
The treatment disease related to osteoporosis.
Probiotics prescription in probiotics calcium functional food of the present invention is：Bifidobacterium infantis 1.0-5.0 hundred million lives
Bacterium, the viable bacterias of bifidobacterium adolescentis 1.0-5.0 hundred million, the viable bacterias of bifidobacterium lactis 1.0-5.0 hundred million, the viable bacterias of Lactobacillus casei 1.0-5.0 hundred million,
The viable bacterias of Lactobacillus rhamnosus 1.0-5.0 hundred million, the preferably viable bacterias of lactobacillus acidophilus 1.0-5.0 hundred million, number of viable 1.5-3.1 hundred million.
Calcium in probiotics calcium functional food of the present invention includes：Calcium carbonate 0.05-0.4g, calcium sulfate 0.05-
0.4g, calcium carbonate or the preferred 0.1-0.2g of calcium sulphate content.
Preferably, the formula of every gram of probiotics calcium functional food of the present invention is：
(1) calcium carbonate 0.1g；
(2) the bifidobacterium infantis freeze-dried powder of the viable bacterias of 3.0-3.1 hundred million, the bifidobacterium adolescentis of the viable bacterias of 3.0-3.1 hundred million are freezed
Powder, the bifidobacterium lactis freeze-dried powder of the viable bacterias of 3.0-3.1 hundred million, the Lactobacillus casei freeze-dried powder of the viable bacterias of 3.0-3.1 hundred million, 3.0-3.1 hundred million
The Lactobacillus rhamnosus freeze-dried powder of viable bacteria, the lactobacillus acidophilus freeze-dried powder of the viable bacterias of 3.0-3.1 hundred million；
(3) inulin 0.1g；
(4) remaining is maltodextrin.
The loose relevant disease of matter of the present invention is：Women postmenopausal estrogen lacks the osteoporosis for causing, chronic
Osteoporosis caused by inflammation, the osteopenia shape caused after cancer bone metastasis etc..
Described chronic inflammation includes rheumatism, rheumatoid arthritis, systemic loupus erythematosus, inflammmatory intestinal disease, silver bits
Disease arthritis, celiac disease, cystic fibrosis, chronic obstructive pulmonary disease and periodontitis.
The preparation method of probiotics calcium functional food of the present invention is：
With probiotics viable bacteria as active ingredient, the calcium carbonate or calcium sulfate of designated ratio are added, be aided with customary adjuvant, led to
Common process is crossed, tablet, capsule, powder, granule, supensoid agent etc. is prepared.
Brief description of the drawings
Fig. 1 formula probiotics can promote the Osteoblast Differentiation of Gegenbaur's cell.OD600=1.0 and OD600=2.0 formulas are prebiotic
Bacterium treatment mouse bone-forming cell system carries out dyeing mirror using alizarin red after MC3T3-E114 days to the skeletonization tubercle of cell
It is fixed, and (acetic acid: glycerine=5: 1) dissolves, measurement 405nm light absorption values are quantified by solvent.
Fig. 2 formula probiotics can significantly raise the activity of alkaline phosphatase.OD600=1.0 probiotics processes mouse
After Gegenbaur's cell system MC3T3-E172 hours, by after protein lysate (10%SDS) cell lysis, with substrate (1.0mg/ml
P-nitrophenyl phosphate, 0.2M TRIS buffers and 5mM magnesium chlorides) the reaction inspection at 405nm in 30 minutes
Survey light absorption value.
Fig. 3 formula probiotics can significantly reduce the serum content of TRAP5 albumen in osteoclastic formation.300ul(1×
109Cfu/ml) probiotics gavage collects serum after two weeks, and the content of TRAP5 is detected by immunity detection reagent (ELISA)
(Fig. 3).
Specific embodiment
Embodiment 1. is formulated facilitation of the probiotics to mouse bone-forming cell system MC3T3-E1 Osteoblast Differentiations.
, in 6cm Tissue Culture Dish, cell will be divided into according to different treatment in certain density MC3T3-E1 cells
Following groups：1. negative control (DMEM)；2. positive control (OPM)；3. probiotics treatment group (MEM+ probiotics OD600 is redissolved
=1.0) and 4. redissolve probiotics treatment group (MEM+ probiotics OD600=2.0).
Daystart is tested, the probiotics that addition sets dosage is processed cell, every 3 days, changed fresh
Culture medium (containing or not contain prescription probiotics).To culture is terminated at the 14th day, culture medium is discarded, cell 3 is rinsed with PBS
Secondary, 4% paraformaldehyde fixes 30 minutes, then rinses cell 3 times with PBS, adds alizarin red dyeing 5 minutes afterwards, finally
Wash 3 times with PBS, finally with solvent (acetic acid: glycerine=5: 1) the alizarin red in cell is dissolved out, by 3000g from
The heart removes cell fragment for 5 minutes, and supernatant is placed in ELIASA detection light absorption value at 405nm.
If cell occurs Osteoblast Differentiation and maturation, the calcium ion in Gegenbaur's cell can be assembled and form skeletonization tubercle, these
Skeletonization tubercle can be by specific chemical dyestuff (alizarin red) come what is detected.The OPM culture mediums used in positive controls
(β-glucophosphate and vitamin C are added in DMEM culture mediums) is that known inducible osteoblast differentiation is ripe
Positive reagent.Therefore the cell of probiotics treatment group is carried when the phenomenon similar with positive controls is showed after Alizarin red staining
Show that probiotics can promote (Fig. 1) of Gegenbaur's cell Osteoblast Differentiation and maturation.
Intracellular alkaline phosphatase activities (ALP) can significantly rise in the osteogenic differentiation process of Gegenbaur's cell,
Intracellular alkaline phosphatase activities after by detecting that formula probiotics processes MC3T3-E1 cells 72 hours, finds relative with the moon
Property control group have significantly rising, and (Fig. 2) similar with positive controls.These results have all pointed out the cell of probiotics treatment
Through the program for entering Osteoblast Differentiation.
The formula probiotics of embodiment 2. can reduce the content of the osteoclastic albumen TRAP5 in ovariectomized mice serum.
Using the Balb/c mouse of 12 week old, wherein being divided into three experimental groups：1. intact animal group, 2. surgery excision ovary
Group, 3. surgery excision ovary group gavage is to 300ul (1 × 109Cfu/ml) probiotics, weekly gavage 3 times continue 4 weeks, and eye socket takes
Blood, room temperature is placed 5 minutes, and 4000rpm is centrifuged 10 minutes, collects serum, is stored in -80 degree refrigerators, stand-by, is exempted from using TRAP5b
Protein content in epidemic disease detection kit detection blood sample.
Typically after ovariectomy, because hormonal readiness change can cause osteoclastic formation to be accelerated, the standard egg of osteoclastic formation
The expression of white TRAP5b can increase, and the content of TRAP5b albumen can reflect the speed of osteoclastic formation in detection blood sample, as a result may be used
See, after mouse ovarian is extractd 4 weeks, TRAP5b protein contents substantially increase in blood sample, and gavage can be reduced effectively to probiotic group
The marker protein TRAP5b levels of osteoclastic formation, osteoclastic formation can be effectively slowed down after illustrating probiotic supplemented.
Finally it should be noted that above example is only used for helping skilled in the art to understand essence of the invention,
The restriction that it goes without doing to protection domain.
Claims (5)
1. a kind of probiotics calcium functional food, it is characterised in that including probiotics and calcium salt, wherein,
(1) the probiotics prescription is：The viable bacterias of bifidobacterium infantis 1.0-5.0 hundred million, the viable bacterias of bifidobacterium adolescentis 1.0-5.0 hundred million,
It is the viable bacterias of bifidobacterium lactis 1.0-5.0 hundred million, the viable bacterias of Lactobacillus casei 1.0-5.0 hundred million, the viable bacterias of Lactobacillus rhamnosus 1.0-5.0 hundred million, thermophilic
The acid viable bacterias of lactobacillus 1.0-5.0 hundred million；
(2) calcium salt is：Calcium carbonate 0.05-0.4g, calcium sulfate 0.05-0.4g；Preferably, the calcium carbonate or calcium sulfate
Content is 0.1-0.2g.
2. functional food according to claim 1, it is characterised in that the formula of every gram described of functional food is：
(1) calcium carbonate 0.1g；
(2) the bifidobacterium infantis freeze-dried powder of the viable bacterias of 3.0-3.1 hundred million, the bifidobacterium adolescentis freeze-dried powder of the viable bacterias of 3.0-3.1 hundred million,
The bifidobacterium lactis freeze-dried powder of the viable bacterias of 3.0-3.1 hundred million, the Lactobacillus casei freeze-dried powder of the viable bacterias of 3.0-3.1 hundred million, the viable bacterias of 3.0-3.1 hundred million
Lactobacillus rhamnosus freeze-dried powder, the lactobacillus acidophilus freeze-dried powder of the viable bacterias of 3.0-3.1 hundred million；
(3) inulin 0.1g；
(4) remaining is maltodextrin.
3. the functional food described in claim 1 or 2 is preparing medicine or the health care of prevention or treatment osteoporosis relevant disease
Application in product, it is characterised in that described osteoporosis relevant disease is that women postmenopausal estrogen lacks the sclerotin for causing
It is loose, osteoporosis caused by chronic inflammation, the osteopenia shape caused after cancer bone metastasis.
4. application according to claim 3, it is characterised in that described chronic inflammation includes rheumatism, rheumatoid joint
Inflammation, systemic loupus erythematosus, inflammmatory intestinal disease, psoriasis arthropathica, celiac disease, cystic fibrosis, chronic obstructive pulmonary
Disease and periodontitis.
5. the preparation method of the probiotics calcium functional food described in claim 1 or 2, it is characterised in that be with probiotics viable bacteria
Active ingredient, adds the calcium carbonate or calcium sulfate of designated ratio, is aided with customary adjuvant, by common process, prepares piece
Agent, capsule, powder, granule, supensoid agent etc..
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611214057.7A CN106858605A (en) | 2016-12-26 | 2016-12-26 | A kind of probiotics calcium functional food for preventing and treating bone information relevant disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611214057.7A CN106858605A (en) | 2016-12-26 | 2016-12-26 | A kind of probiotics calcium functional food for preventing and treating bone information relevant disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106858605A true CN106858605A (en) | 2017-06-20 |
Family
ID=59164002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611214057.7A Pending CN106858605A (en) | 2016-12-26 | 2016-12-26 | A kind of probiotics calcium functional food for preventing and treating bone information relevant disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106858605A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109527538A (en) * | 2018-11-07 | 2019-03-29 | 云南金霓尔生物科技有限公司 | It is a kind of to treat sorbefacient nutritional agents of osteoporosis and preparation method thereof |
| CN110959792A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Solid beverage containing bifidobacterium lactis and application thereof |
| CN111109607A (en) * | 2020-01-10 | 2020-05-08 | 青岛康益生物科技有限公司 | A health food for preventing and treating osteoporosis |
| CN111419882A (en) * | 2020-05-26 | 2020-07-17 | 北京科拓恒通生物技术股份有限公司 | Bifidobacterium lactis for preventing and treating osteoporosis and application thereof |
| US11911423B2 (en) | 2018-09-30 | 2024-02-27 | Inner Mongolia Yili Industrial Group Co., Ltd. | Bifidobacterium lactis BL-99 and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001015715A2 (en) * | 1999-08-31 | 2001-03-08 | Societe Des Produits Nestle S.A. | Composition for maintenance of bone or dental health or treatment of bone or dental disorders |
| CN103889241A (en) * | 2011-10-18 | 2014-06-25 | 雀巢产品技术援助有限公司 | Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease |
| EP2818056A1 (en) * | 2013-06-25 | 2014-12-31 | Biosearch S.A. | Probiotic bacteria comprising metals, metal nanoparticles and uses thereof |
| CN105055458A (en) * | 2015-06-15 | 2015-11-18 | 山东凤凰生物有限公司 | Probiotic preparation for preventing and treating osteoporosis, and preparation method thereof |
| CN105188723A (en) * | 2013-04-03 | 2015-12-23 | 普罗比公司 | Probiotic strains for use in treatment or prevention of osteoporosis |
| CN105942505A (en) * | 2016-05-13 | 2016-09-21 | 四川子仁制药有限公司 | Recipe and preparation method of quintuplet probiotic nutritional powder |
| CN106177922A (en) * | 2016-09-07 | 2016-12-07 | 海南金海岸生物技术研究所 | A kind of composite collagen gel increasing bone density, prevention senile osteoporosis and preparation method thereof |
-
2016
- 2016-12-26 CN CN201611214057.7A patent/CN106858605A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001015715A2 (en) * | 1999-08-31 | 2001-03-08 | Societe Des Produits Nestle S.A. | Composition for maintenance of bone or dental health or treatment of bone or dental disorders |
| CN103889241A (en) * | 2011-10-18 | 2014-06-25 | 雀巢产品技术援助有限公司 | Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease |
| CN105188723A (en) * | 2013-04-03 | 2015-12-23 | 普罗比公司 | Probiotic strains for use in treatment or prevention of osteoporosis |
| EP2818056A1 (en) * | 2013-06-25 | 2014-12-31 | Biosearch S.A. | Probiotic bacteria comprising metals, metal nanoparticles and uses thereof |
| CN105055458A (en) * | 2015-06-15 | 2015-11-18 | 山东凤凰生物有限公司 | Probiotic preparation for preventing and treating osteoporosis, and preparation method thereof |
| CN105942505A (en) * | 2016-05-13 | 2016-09-21 | 四川子仁制药有限公司 | Recipe and preparation method of quintuplet probiotic nutritional powder |
| CN106177922A (en) * | 2016-09-07 | 2016-12-07 | 海南金海岸生物技术研究所 | A kind of composite collagen gel increasing bone density, prevention senile osteoporosis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 卢胜娟，等: "益生菌的生理功能及其安全性", 《食品研究与开发》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110959792A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Solid beverage containing bifidobacterium lactis and application thereof |
| CN110959792B (en) * | 2018-09-30 | 2022-03-29 | 内蒙古伊利实业集团股份有限公司 | Solid beverage containing bifidobacterium lactis and application thereof |
| US11911423B2 (en) | 2018-09-30 | 2024-02-27 | Inner Mongolia Yili Industrial Group Co., Ltd. | Bifidobacterium lactis BL-99 and application thereof |
| US11911422B2 (en) * | 2018-09-30 | 2024-02-27 | Inner Mongolia Yili Industrial Group Co., Ltd. | Bifidobacterium lactis BL-99 and application thereof |
| CN109527538A (en) * | 2018-11-07 | 2019-03-29 | 云南金霓尔生物科技有限公司 | It is a kind of to treat sorbefacient nutritional agents of osteoporosis and preparation method thereof |
| CN111109607A (en) * | 2020-01-10 | 2020-05-08 | 青岛康益生物科技有限公司 | A health food for preventing and treating osteoporosis |
| CN111419882A (en) * | 2020-05-26 | 2020-07-17 | 北京科拓恒通生物技术股份有限公司 | Bifidobacterium lactis for preventing and treating osteoporosis and application thereof |
| CN111419882B (en) * | 2020-05-26 | 2022-07-29 | 北京科拓恒通生物技术股份有限公司 | Bifidobacterium lactis for preventing and treating osteoporosis and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lyons et al. | Breast milk, a source of beneficial microbes and associated benefits for infant health | |
| CN106858605A (en) | A kind of probiotics calcium functional food for preventing and treating bone information relevant disease | |
| Sharifi-Rad et al. | Probiotics: versatile bioactive components in promoting human health | |
| Santacroce et al. | A successful history: probiotics and their potential as antimicrobials | |
| Gao et al. | Yak-milk-derived exosomes promote proliferation of intestinal epithelial cells in an hypoxic environment | |
| Bengmark | Bioecologic control of the gastrointestinal tract: the role of flora and supplemented probiotics and synbiotics | |
| Shin et al. | A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome | |
| Vitetta et al. | Probiotics, prebiotics and the gastrointestinal tract in health and disease | |
| Wang et al. | Fermented milk containing Lactobacillus casei Zhang and Bifidobacterium animalis ssp. lactis V9 alleviated constipation symptoms through regulation of intestinal microbiota, inflammation, and metabolic pathways | |
| Fernández et al. | Strategies for the preservation, restoration and modulation of the human milk microbiota. Implications for human milk banks and neonatal intensive care units | |
| RU2767967C2 (en) | Probiotics use for psoriasis treatment and/or prevention | |
| Surono et al. | Effect of probiotic L. plantarum IS-10506 and zinc supplementation on humoral immune response and zinc status of Indonesian pre-school children | |
| Kamng’ona Arox et al. | Provision of lipid-based nutrient supplements to mothers during pregnancy and 6 months postpartum and to their infants from 6 to 18 months promotes infant gut microbiota diversity at 18 months of age but not microbiota maturation in a rural Malawian setting: secondary outcomes of a randomized trial | |
| CN108289918A (en) | Ai Keman bacterium through pasteurization are used to treat the purposes of metabolic disorder | |
| Martinello et al. | Effects of probiotic intake on intestinal bifidobacteria of celiac patients | |
| GB2528342A (en) | Lactobacillus strain, composition and use thereof for treating syndromes and related complications of autoimmune diseases | |
| Takáčová et al. | Any future for faecal microbiota transplantation as a novel strategy for gut microbiota modulation in human and veterinary medicine? | |
| KR20200014818A (en) | Hypoglycemic Effects of Bacillus Coagulum | |
| CN104017746B (en) | Lactobacillus, its composition and the application for preparing heart and hepatic disease caused by treatment erythematosus lupus | |
| Abboud et al. | Gut microbiome, probiotics and bone: An updated mini review | |
| Marzorati et al. | Effects of combined prebiotic, probiotic, IgG and amino acid supplementation on the gut microbiome of patients with inflammatory bowel disease | |
| Skoufou et al. | The networked interaction between probiotics and intestine in health and disease: a promising success story | |
| Al-Qysi et al. | Investigating the characteristics of probiotics marketed in the Middle East and pharmacists' perception of use in Muscat, Oman | |
| Marcelo et al. | Probiotic therapy outcomes in body composition of children and adolescent with obesity, a nonrandomized controlled trial | |
| Alves et al. | Immunomodulatory effects of different strains of Lactococcus lactis in DSS-induced colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 134000 room 118, No. four, muddy road, Tonghua Development Zone, Tonghua, Jilin, 999-999/551-077 Applicant after: JILIN SHURUN PHARMACEUTICAL Co.,Ltd. Address before: 134000 room 118, No. four, muddy road, Tonghua Development Zone, Tonghua, Jilin, 999-999/551-077 Applicant before: JILIN SHURUN BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230626 Address after: Room 201, Building 32, Anhua Xili 1st District, Chaoyang District, Beijing, 100011 Applicant after: Li Zhimin Address before: Room 118, No. 999-999/551-077, Sihun Highway, Tonghua Development Zone, Jilin Province, 134000 Applicant before: JILIN SHURUN PHARMACEUTICAL Co.,Ltd. |